Australia’s CSL reiterates manufacturing commitment with AstraZeneca COVID-19 vaccine


Article content

Australian biotech CSL said on Thursday it was committed to its manufacturing agreement of about 50 million doses with AstraZeneca’s COVID-19 vaccine into 2022.

The announcement came after a media report said AstraZeneca’s vaccine, Vaxzevria, will no longer be manufactured in Australia due to demand for vaccines of Pfizer and Moderna. (Reporting by Indranil Sarkar in Bengaluru)